Arpita Maiti, PhD

North Chicago, Illinois, United States
Arpita joined AbbVie in 2021 as the Head of Immunology Search & Evaluation (S&E) leading a team that identifies and assesses external opportunities for the Immunology therapeutic area, from discovery to launched products. Transactions that Immunology S&E executed recently include Dragonfly and Cugene. She came to AbbVie after 7 years at Pfizer in roles of increasing responsibility in Emerging Science & Innovation (ES&I), where she led scouting (Idea to Candidate) for the Inflammation & Immunology research unit and the Centers for Therapeutic Innovation. She also led strategy and partnering efforts in the microbiome for Pfizer. Deals for which Arpita was responsible at Pfizer include Evotec, Biorap, CytoReason, Theravance, and equity investments and licenses with AnTolRx and Imcyse. Prior to Pfizer, she was Associate Director of R&D Alliance Design & Management at Vertex Pharmaceuticals. Arpita got her start in biotech at Angiotech Pharmaceuticals, heading the Cell Biology & Drug Screening group. She trained as an immunologist and has a PhD and MSc in Immunology from UBC and a BSc from Trinity College, UofT. Arpita co-organized the 12th World Congress on Inflammation held in 2015, served on the board of the Inflammation Research Association in numerous positions, including as its President (2012-14), and is currently on the Executive Committee of the International Association of Inflammation Societies.
Speaking In
10:30 AM - 10:45 AM (PDT)
Wednesday, June 15
AbbVie is a global, research-based biopharmaceutical company committed to delivering innovative…